Screening for vaccinia virus egress inhibitors: separation of IMV, IEV, and EEV.
Concerns about the possible use of variola virus as a biological weapon as well as the need for therapeutics for the treatment or prevention of naturally acquired poxvirus infections or vaccination complications have led to the search for small molecule inhibitors of poxvirus replication. One unique and attractive target for antiviral development is viral egress. Part of understanding the mechanism of action of viral egress inhibitors involves determining which virion form is being made. This can be accomplished through buoyant density centrifugation.
SIGA Technologies, Inc., Corvallis, OR, USA.
Chelsea M
CM
Byrd
Dennis E
DE
Hruby
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D015153:Blotting, Western; D002460:Cell Line; D002499:Centrifugation, Density Gradient; D004353:Drug Evaluation, Preclinical / Q000379:methods; D054833:Isoindoles / Q000494:pharmacology*; D011817:Rabbits; D014616:Vaccinia virus / Q000187:drug effects* / Q000302:isolation & purification / Q000502:physiology; D014764:Viral Proteins / Q000378:metabolism; D014771:Virion / Q000187:drug effects; D014776:Virus Cultivation; D057074:Virus Release / Q000187:drug effects*; D014779:Virus Replication / Q000187:drug effects; D010797:Phthalimides
D000998:Antiviral Agents; D001549:Benzamides; D054833:Isoindoles; D014764:Viral Proteins; C505045:tecovirimat; D010797:Phthalimides